ORMP
Oramed Pharmaceuticals Inc.
There isn't enough reported data to score ORMP yet.
ORMP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Unavailable |
ORMP's profitability is currently strong. There isn't enough data to rate its revenue, cash flow and balance sheet.
ORMP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.2x | $4.03 | — |
| Cheap | 1.5x | $5.25 | +30% |
| Fair | 5.7x | $19.40 | +381% |
| Expensive | 85x | $290 | +7101% |
Historical ranges are pointers, not guarantees.
ORMP's PE is 1.2x, but its earnings don't support one, so it isn't a reliable read right now.
ORMP Forward outlook
There aren't enough analyst estimates for ORMP to show an outlook.
ORMP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $3.43 | +246% |
| Q2 2026 | $4.13 | +$4.75 |
| Q1 2026 | $2.60 | +$3.31 |
| Q4 2025 | $1.50 | +$1.98 |
| Q3 2025 | $0.99 | +$1.03 |
| Q2 2025 | -$0.62 | -272% |
| Q1 2025 | -$0.71 | -745% |
| Q4 2024 | -$0.48 | -443% |
ORMP earned $3.43 per share over the past year, about three times what it earned the year before.
ORMP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $674K | 0% |
| Q1 2023 | $666K | 0% |
| Q4 2022 | $681K | -25% |
| Q3 2022 | $682K | -0.1% |
| Q2 2022 | $674K | -1% |
| Q1 2022 | $666K | +0.2% |
| Q4 2021 | $904K | +34% |
| Q4 2021 | $674K | 0% |
ORMP's revenue is growing: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2025 | -225% | N/A |
| Q2 2023 | -562% | +1132 points |
| Q1 2023 | -782% | +908 points |
| Q4 2022 | -1430% | -67 points |
| Q3 2022 | -1201% | -4.9 points |
| Q2 2022 | -1694% | -609 points |
| Q1 2022 | -1689% | -791 points |
| Q4 2021 | -1364% | -632 points |
ORMP's operating margin was −225% last quarter, up 976 points from the same quarter a year ago, near the top of its range since 2020.
ORMP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $422K | +$2M |
| Q2 2026 | -$202K | +$3.3M |
| Q1 2026 | -$2.9M | +$602K |
| Q4 2025 | -$468K | +$1.5M |
| Q3 2025 | -$1.6M | +$5.5M |
| Q2 2025 | -$3.5M | -270% |
| Q1 2025 | -$3.5M | -$2M |
| Q4 2024 | -$1.9M | -$501K |
ORMP has burned cash in almost every quarter: −$3M over the past year, against −$11M the year before.
ORMP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +514K shares |
| 1 year | +0.6% | +241K shares |
| 3 years | +6.4% | +2.6M shares |
| 5 years | +17% | +6.3M shares |
| Available history | +141% | +25.2M shares |
ORMP has 43M diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $4M |
| Q3 2025 | $361,000 |
| Q4 2024 | $1.2M |
ORMP Net Leverage
ORMP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 8.9 | Oversold |
ORMP's weekly RSI is 47 (neutral) and its Stochastic is 9 (oversold).
ORMP PE vs Healthcare Sector
| Metric | ORMP | Sector median | Relative |
|---|---|---|---|
| PE | 1.2x | 26x | 95% below |
| PE % | 10 | 29 | 19 pts below |
ORMP is trading at 1.2x earnings, a 95% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ORMP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.22 | 4.5% below |
| 20 week MA | $4.38 | 8% below |
| 50 week MA | $3.89 | 3.6% above |
| 100 week MA | $3.08 | 31% above |
| 200 week MA | $2.83 | 42% above |
ORMP has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 42% above its 200-week average.
ORMP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.18 | $4.54 | -12% |
| 2021 | $4.54 | $15.5 | +242% |
| 2022 | $15.5 | $11.0 | -29% |
| 2023 | $11.0 | $2.31 | -79% |
| 2024 | $2.31 | $2.37 | +2.6% |
| 2025 | $2.37 | $2.95 | +24% |
| 2026 YTD | $2.95 | $4.03 | +37% |
ORMP's yearly returns have swung widely, from +242% in 2021 to −79% in 2023. It's up 37% so far in 2026.